Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
基本信息
- 批准号:10593908
- 负责人:
- 金额:$ 181.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AdoptedAdoptionAdvocateAgeAlabamaBlue CrossBlue ShieldBostonBreastBreast Cancer DetectionBreast Cancer Risk FactorBreast Cancer TreatmentCaliforniaCancer BiologyCaringChicagoClinicalClinical ServicesCollaborationsConflict (Psychology)ConfusionContractsCountryDataDiseaseEmployeeEnrollmentEthnic OriginExhibitsFamilyFeedbackFloridaFrequenciesFundingGenesGenetic Predisposition to DiseaseGeographyGoalsGuidelinesHealthHealthcareHomeIllinoisIndividualInfrastructureInheritedInsurance CarriersInsurance CoverageIntentionInternationalInternistInvestmentsKnowledgeLearningLouisianaMalignant NeoplasmsMammographyMeasuresMidwestern United StatesMinnesotaModalityModelingModernizationMutationNew JerseyOregonOutcomeParalysedParticipantPatient-Focused OutcomesPopulationPopulation HeterogeneityPredispositionRandomizedRecommendationRecording of previous eventsResearch InstituteRiskRisk AssessmentRisk FactorsSafetyScienceSecureSingle Nucleotide PolymorphismSiteSocietiesSouth CarolinaTarget PopulationsTechnologyTestingTimeTractionTranslatingUnited StatesUnited States Department of Veterans AffairsUniversitiesUpdateUtahVariantVeteransWashingtonWomanarmbreast densitycancer predispositionclinical research sitecomorbiditycostdemographicsdesignexperiencehigh riskimprovedindividualized medicineinnovationknowledge translationlearning progressionmalignant breast neoplasmoutreachpatient orientedpersonalized approachpersonalized screeningpolygenic risk scorepopulation basedpragmatic trialprecision medicinepreferencepreventive interventionprogramspsychologicrecruitroutine screeningscreeningscreening guidelinessocioeconomicsstudy populationtesting servicestrial comparingtrial designtrial enrollmentuptake
项目摘要
PROJECT SUMMARY/ABSTRACT
The WISDOM Study (Women Informed to Screen Depending on Measures of risk) is a
pragmatic trial comparing a personalized approach to breast cancer screening – in which the
intensity and modality of screening is dependent upon stratified personal risk -- against the gold
standard of annual screening. The goal is to determine whether a personalized approach is as
safe, less morbid, better accepted by women, encourages uptake of preventive interventions,
and is of higher health care value (better outcomes at less cost psychologically, physically, and
financially).
In this proposal `Expanding the WISDOM Study's Diversity, Reach, and Generalizability', we are
seeking support to expand the study to additional sites around the country to enhance
recruitment, improve study power and increase both the geographic and population diversity of
study participants. By doing so, our intention is to increase the generalizability of the study
results. Using a unique coverage with evidence progression model, we have secured insurance
coverage and outreach collaboration from multiple payers, giving us the opportunity to enroll
from an additional population of ~6 million women across multiple regions and varied ethnic and
socioeconomic backgrounds. The network of sites that this proposal will enable us to add will
allow us to create a collaborative group to continuously improve screening and learn who is at
risk for what kind of cancer.
The personalized screening arm includes a risk assessment based on family history, exposures,
breast density, co-morbidity and genetic predisposition (presence of mutations in the 9 genes
associated with screening and the combination of the small variation in inherited genes, the
single nucleotide polymorphisms, into a polygenic risk score or PRS). Importantly, the PRS
score is tailored to different ethnicities based on advances in the science of risk assessment,
allowing us to translate these important findings into practice. We are using an adaptive
approach in which the risk model is updated over the course of the trial as new information
emerges. The personalized approach yields an integrated risk score that allows us to assign an
age to start, an age to stop, a frequency of screening, and a modality for screening.
The R01 Specific Aims are to:
1. Open new clinical sites with experience enrolling targeted populations and use culturally
targeted materials to increase the numbers in and diversity of the WISDOM study
population
2. Enhance trial enrollment and retention through national partnerships, centralized campaigns
across the network and embedded analytics with real time feedback
项目总结/摘要
WISDOM研究(根据风险衡量标准进行筛查的女性)是一项
一项比较个性化乳腺癌筛查方法的实用性试验,
筛查的强度和方式取决于分层的个人风险--相对于黄金
年度筛查标准。目标是确定个性化方法是否符合
安全、不那么病态、更容易被妇女接受,鼓励采取预防性干预措施,
并且具有更高的医疗保健价值(在心理、身体和心理上以更低的成本获得更好的结果),
财政上)。
在这份“扩大WISDOM研究的多样性、范围和普遍性”的提案中,我们
寻求支持,将研究扩大到全国其他地点,
招募,提高学习能力,增加地理和人口多样性,
研究参与者。这样做的目的是为了增加研究的普遍性
结果使用独特的覆盖范围与证据进展模型,我们已获得保险
来自多个付款人的覆盖范围和推广合作,使我们有机会注册
来自多个地区和不同种族的约600万妇女的额外人口,
社会经济背景。这个建议将使我们能够增加的网站网络将
允许我们创建一个协作组,以不断改进筛选,并了解谁是在
哪种癌症的风险。
个性化筛查包括基于家族史、暴露、
乳腺密度、合并症和遗传易感性(9个基因中存在突变
与筛选和遗传基因中的小变异相结合,
单核苷酸多态性转化为多基因风险评分或PRS)。重要的是,PRS
根据风险评估科学的进步,
使我们能够将这些重要的发现转化为实践。我们使用的是一种自适应的
在试验过程中将风险模型作为新信息进行更新的方法
出现了个性化的方法产生一个综合风险评分,使我们能够分配一个
开始的年龄、停止的年龄、筛查的频率和筛查的方式。
R 01的具体目标是:
1.开设新的临床研究中心,具有招募目标人群的经验,并在文化上使用
有针对性的材料,以增加WISDOM研究的数量和多样性
人口
2.通过国家合作伙伴关系、集中活动加强试验入组和保留
并通过真实的时间反馈进行嵌入式分析
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAURA J ESSERMAN其他文献
LAURA J ESSERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAURA J ESSERMAN', 18)}}的其他基金
Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical Implications
增强 WISDOM 临床试验参与者的多样性:实际挑战和伦理影响
- 批准号:
10367828 - 财政年份:2020
- 资助金额:
$ 181.76万 - 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
- 批准号:
10368970 - 财政年份:2020
- 资助金额:
$ 181.76万 - 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
- 批准号:
9888251 - 财政年份:2020
- 资助金额:
$ 181.76万 - 项目类别:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
I-SPY2:改进 I-SPY 2 试验,纳入 MRI 引导的适应性序贯治疗,以优化乳腺癌结果
- 批准号:
9789198 - 财政年份:2017
- 资助金额:
$ 181.76万 - 项目类别:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
I-SPY2:改进 I-SPY 2 试验,纳入 MRI 引导的适应性序贯治疗,以优化乳腺癌结果
- 批准号:
10013133 - 财政年份:2017
- 资助金额:
$ 181.76万 - 项目类别:
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
I SPY 2.2 试验:演变为影像学和分子生物标志物反应指导的适应性序贯治疗以优化乳腺癌结果
- 批准号:
10628608 - 财政年份:2017
- 资助金额:
$ 181.76万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 181.76万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 181.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 181.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 181.76万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 181.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 181.76万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 181.76万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 181.76万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 181.76万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 181.76万 - 项目类别:
Standard Grant